← 治験一覧に戻る
急性虚血性脳卒中におけるMCI-186の用量設定試験
基本情報
- NCT ID
- NCT03346538
- ステータス
- 中止
- 試験のフェーズ
- 第2相
- 試験タイプ
- 介入
- 目標被験者数
- 17
- 治験依頼者名
- Tanabe Pharma Corporation
概要
To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen (administration twice daily for 14 days) as the control.
対象疾患
Acute Ischemic Stroke
介入
Continuous infusion high-dose MCI-186(DRUG)
Continuous infusion low-dose MCI-186(DRUG)
Continuous infusion placebo(DRUG)
Approved dosing regimen MCI-186(DRUG)
Approved dosing regimen placebo(DRUG)
依頼者（Sponsor）
田辺ファーマ株式会社(INDUSTRY)